<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064181</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40015</org_study_id>
    <secondary_id>EORTC-40015</secondary_id>
    <nct_id>NCT00064181</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as irinotecan, capecitabine, leucovorin, and
      fluorouracil use different ways to stop tumor cells from dividing so they stop growing or
      die. Celecoxib may stop the growth of colorectal cancer by stopping blood flow to the tumor.
      It is not yet known which combination chemotherapy regimen with or without celecoxib is more
      effective in treating metastatic colorectal cancer.

      PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens
      and celecoxib to see how well they work compared to two combination chemotherapy regimens
      alone in treating patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the progression-free survival of patients with metastatic colorectal cancer
           treated with capecitabine and irinotecan vs fluorouracil, leucovorin calcium, and
           irinotecan with vs without celecoxib.

        -  Compare the safety of these regimens in these patients.

        -  Compare the response rate in patients treated with these regimens.

        -  Compare the time to treatment failure and overall survival of patients treated with
           these regimens.

      OUTLINE: This is a randomized, double-blind*, multicenter study. Patients are stratified
      according to participating center, prior adjuvant therapy (yes vs no), and risk group (poor
      vs intermediate vs good). Patients are randomized to 1 of 4 treatment arms.

        -  Arm I: Patients receive irinotecan IV over 30-90 minutes on days 1 and 22; oral
           capecitabine twice daily on days 1-15 and 22-36; and oral celecoxib twice daily on days
           1-42.

        -  Arm II: Patients receive irinotecan and capecitabine as in arm I and oral placebo twice
           daily on days 1-42.

        -  Arm III: Patients receive irinotecan IV over 30-90 minutes on days 1, 15, and 29;
           leucovorin calcium (CF) IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days
           1, 2, 15, 16, 29, and 30; and oral celecoxib twice daily on days 1-42.

        -  Arm IV: Patients receive irinotecan, CF, and 5-FU as in arm III and oral placebo twice
           daily on days 1-42.

      In all arms, treatment repeats every 6 weeks for up to 6 courses in the absence of disease
      progression or unacceptable toxicity. If all chemotherapy is discontinued due to toxicity,
      patients may continue celecoxib or placebo until disease progression, unacceptable toxicity,
      or starting a new cytotoxic regimen.

      NOTE: *The double-blind treatment only applies to the celecoxib and placebo randomization

      Patients are followed every 2 months.

      PROJECTED ACCRUAL: A total of 692 patients (173 per treatment arm) will be accrued for this
      study within 3.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">86</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the colon or rectum

          -  Metastatic disease

          -  Measurable disease

               -  Patients who received prior radiotherapy must have measurable or evaluable
                  disease outside the radiotherapy field

          -  No CNS metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

          -  AST and ALT no greater than 2.5 times ULN (5 times ULN in the presence of liver
             metastases)

        Renal

          -  Creatinine clearance at least 51 mL/min

          -  No severe renal impairment

        Cardiovascular

          -  No severe cardiac disease

          -  No uncontrolled angina pectoris

          -  No myocardial infarction within the past 6 months

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

          -  No active Crohn's disease

          -  No other malignancy except adequately treated carcinoma in situ of the cervix or
             nonmelanoma skin cancer

          -  No other uncontrolled severe medical condition

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent active or passive immunotherapy for colon cancer

        Chemotherapy

          -  No prior chemotherapy for metastatic disease

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  At least 6 months since prior adjuvant therapy

          -  More than 4 weeks since prior investigational drugs

          -  No concurrent sorivudine or chemically related analogues (e.g., brivudine)

          -  No other concurrent investigational drugs

          -  No other concurrent cytotoxic agents

          -  No concurrent prophylactic fluconazole

          -  No concurrent or planned cyclo-oxygenase-2 (COX-2) inhibitors or nonsteroidal
             anti-inflammatory drugs

          -  No concurrent chronic use of full-dose aspirin (325 mg/day or greater)

               -  Concurrent low-dose (cardioprotective) aspirin prophylaxis (no more than 325 mg
                  every other day OR no more than 162.5 mg per day) allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus-Henning Koehne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Oldenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Network Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cazk Groeninghe - Campus St-Niklaas</name>
      <address>
        <city>Kortrijk</city>
        <zip>B-8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Ziekenhuis</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Cairo</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carl Carus</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <zip>D-45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Albert - Ludwigs - Universitaet Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Hagen</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien Hospital</name>
      <address>
        <city>Hamm</city>
        <zip>59065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>D-67653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinzentiuskrankenhaus</name>
      <address>
        <city>Landau</city>
        <zip>D-76829</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Leer</name>
      <address>
        <city>Leer</city>
        <zip>D-26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Meissen</name>
      <address>
        <city>Meissen</city>
        <zip>D-01662</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universitaet</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Hautklinik Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008 May;19(5):920-6. Epub 2007 Dec 6.</citation>
    <PMID>18065406</PMID>
  </results_reference>
  <results_reference>
    <citation>De Grève J, Koehne C, Hartmann J, et al.: Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015. [Abstract] J Clin Oncol 24 (Suppl 18): A-3577, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Kohne C, De Greve J, Bokemeyer C, et al.: Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. [Abstract] J Clin Oncol 23 (Suppl 16): A-3525, 252s, 2005.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

